http://www.sirweb.org/news/newsPDF/SIR_ ... t_JVIR.pdf
Lot of good observations (and some well deserved snub to existing "stakeholders")
Despite the use of current therapies that aim to reduce inflammation, interrupt specific components of the immune system, or prevent neurodegeneration, most patients with MS exhibit a disease course that includes periodic acute relapses that initially resolve but eventually lead to significant clinical deterioration and disability (11–14). Existing MS therapies can also cause disabling side effects that can lead to additional morbidity, precluding the use of such therapies in many patients (14). Therefore, new innovative therapies for MS are urgently required.
SIR recognizes that patients with MS constitute a particularly vulnerable
population, whose safety must be protected as new therapeutic
approaches are evaluated.
At present, SIR considers the published
literature to be inconclusive on whether CCSVI is a clinically
important factor in the development and/or progression of MS,
and on whether balloon angioplasty and/or stent placement are
clinically effective in patients with MS.
